BCIQ Profiles

Company Profile Report
0422 Monopteros Medicxi
BioCentury & Getty Images

Emerging Company Profile

Monopteros: Medicxi-backed start-up believes MALT1 inhibition can prime tumors for checkpoint blockade

Emerging Company Profile: Monopteros’ $20M round to support Phase I/Ib trial, first in solid tumors

With $20M from the asset-centric investor, Monopteros aims to complete a Phase I/Ib trial that would be the first of a MALT1 program for solid tumors.

Read the full 626 word article

How to gain access

Continue reading with a
two-week free trial.